MIRACL study, atorvastatin

Last reviewed 01/2018

Summary points regarding this study are presented:

  • objective - to determine whether atorvastatin, 80 mg/d, initiated 24-96 hours after an acute coronary syndrome, reduces death and nonfatal ischaemic events
  • trial design - randomized double-blind, follow-up through 16 weeks
  • patients - 3086 patients (aged 18 years or older) with unstable angina or nonQ-wave acute myocardial infarction
  • main outcome measures - primary end point defined as death, nonfatal acute myocardial infarction, recurrent myocardial ischaemia with objective evidence and requiring emergency hospitalisation, or cardiac arrest with resuscitation
  • results - no significant differences in risk of death, nonfatal myocardial infarction, or cardiac arrest between the atorvastatin group and the placebo group, although the atorvastatin group had a lower risk of symptomatic ischaemia with objective evidence and requiring hospitalisation (6.2% Vs 8.4%; RR, 0.74; 95% CI, 0.57-0.95; P=.02)
  • conclusion - lipid lowering treatment with atorvastatin, 80mg/d, for patients with acute coronary syndrome, reduces ischaemic events in the first 16 weeks, mostly recurrent symptomatic ischaemic requiring hospitalisation


  1. Schwartz GC et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - the MIRACL Study: A randomized controlled trial. JAMA 2001; 285 (13): 1711-1718.